An Integrated Taguchi Design and Response Surface Methodological Approach for Development of Bedaquiline-Loaded Nanostructured Lipid Carriers; [Tasarım Deney Yöntemi Kullanılarak Nanoyapılı Lipid Taşıyıcılar, Tabletler ve İnsan Plazmasında Bedaquilin Fumarat Tayini İçin RP-HPLC Yönteminin Geliştirilmesi ve Validasyonu]

Open

Rachmat Mauludin, Asti RAHAYU Satrialdi, Neng Fisheri Kurniati

2026 Fabad Journal of Pharmaceutical Sciences Vol. 51 Issue 1 Article Cited by 0 Quartile

Abstract

Bedaquiline (BDQ), a poorly water-soluble drug, was successfully encapsulated in nanostructured lipid carriers (NLCs) to enhance its physicochemical properties. For the first time, BDQ-NLCs were optimized using a hybrid Taguchi and central composite design (CCD) methodology. This study selected cetyl palmitate, caprylic triglyceride, and Plantacare® 1200 in formulation development. The independent variables in this study, based on the Taguchi design approach, include the solid-liquid binary ratio, the surfactant concentration, and the sonication time. The dependent variables include particle size, encapsulation efficiency, and drug loading. The optimized BDQ-NLCs exhibited a particle size of 153.5 ± 2.3 nm, an encapsulation efficiency of 94.46 ± 0.09%, and a drug loading capacity of 3.04 ± 0.02%. The characterization of the optimum BDQ-NLCs revealed a zeta potential of -47.75 mV, a round particle morphology, and an endothermic event occurring between 45.94 and 54.60°C, indicating a transformation phase from solid to liquid. In vitro drug release profiles demonstrated that the optimized BDQ-NLCs formulation provides controlled and pH-dependent drug release, governed by a diffusion-driven mechanism. The stability evaluation of BDQ-NLCs demonstrated consistent stability under refrigerated conditions, while significant particle growth was observed at 25°C and 40°C, indicating temperature-dependent stability. Therefore, the developed BDQ-NLC formulation represents a physicochemically optimized system that may serve as a platform for further development of BDQ delivery, with therapeutic potential to be validated in future biological studies.

Affiliations

Department of Pharmaceutics, School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia; Program Doctoral, School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia; Department of Pharmaceutics, Faculty of Health Sciences, Universitas PGRI Adi Buana Surabaya, Indonesia; Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia

Research at a Glance

Premium content — register to unlock

Research at a Glance

Register to unlock

Topics & SDG Alignment

Premium content — register to unlock

Topics & SDG Alignment

Register to unlock

Collaboration

Premium content — register to unlock

Collaboration

Register to unlock

Author Profile (Selected)

Premium content — register to unlock

Author Profile (Selected)

Register to unlock

References Overview

Premium content — register to unlock

References Overview

Register to unlock

Journal & Source

Premium content — register to unlock

Journal & Source

Register to unlock

Metadata & Integrity

Premium content — register to unlock

Metadata & Integrity

Register to unlock